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1) The Nobel Prize in Medicine 2018 Awarded for 
Discovery of CTLA-4 and PD-1
On 1 October 2018, the Nobel Assembly at Karolinska 
Institute has decided to award the 2018 Nobel Prize in Physiol-
ogy or Medicine jointly to James P. Allison and Tasuku Honjo 
“for their discovery of cancer therapy by inhibition of negative 
immune regulation”. By stimulating the inherent ability of im-
mune system to attack tumour cells this year’s Nobel Laureates 
have established an entirely new principle for cancer therapy. 
For more than 100 years scientists attempted to engage the 
immune system in the fight against cancer. A number of thera-
peutic approaches are available for cancer treatment, including 
surgery, radiation, and other strategies, some of which have 
been awarded previous Nobel Prizes. These include methods 
for hormone treatment for prostate cancer (Huggins, 1966), 
chemotherapy (Elion and Hitchins, 1988), and bone marrow 
transplantation for leukaemia (Thomas 1990). However, ad-
vanced cancer remains immensely difficult to treat, and novel 
therapeutic strategies are desperately needed.
In the late 19th century and beginning of the 20th century 
the concept emerged that activation of the immune system 
might be a strategy for attacking tumour cells. Attempts were 
made to infect patients with bacteria to activate the defense. 
These efforts only had modest effects, but a variant of this 
strategy is used today in the treatment of bladder cancer. 
Despite remarkable scientific progress, attempts to develop 
generalizable new strategies against cancer proved difficult. 
The fundamental property of our immune system is the ability 
to discriminate “self” from “non-self” so that invading bacteria, 
viruses and other dangers can be attacked and eliminated. T 
cells are key players in this defense. T cells were shown to 
have receptors that bind to structures recognised as non-self 
and such interactions trigger the immune system to engage in 
defense. But additional proteins acting as T-cell accelerators 
are also required to trigger a full-blown immune response. 
Many scientists contributed to this important basic research 
and identified other proteins that function as brakes on the 
T cells, inhibiting immune activation. This intricate balance 
between accelerators and brakes is essential for tight control. 
It ensures that the immune system is sufficiently engaged in 
attack against foreign microorganisms while avoiding the 
excessive activation that can lead to autoimmune destruction 
of healthy cells and tissues. 
During the 1990s, in his laboratory at the University of 
California, Berkeley, James P. Allison studied the T-cell protein 
CTLA-4. He was one of several scientists who had made the 
observation that C TLA-4 functions as a brake on T cells. 
Other research teams exploited the mechanism as a target in 
the treatment of autoimmune disease. Allison, however, had an 
entirely different idea. He had already developed an antibody 
that could bind to CTLA-4 and block its function. He now set 
out to investigate if CTLA-4 blockade could disengage the 
T-cell brake and unleash the immune system to attack cancer 
cells. Allison and co-workers performed a first experiment at 
the end of 1994, and in their excitement it was immediately 
repeated over the Christmas break. The results were spectacu-
lar. Mice with cancer had been cured by treatment with the 
antibodies that inhibit the brake and unlock antitumor T-cell 
activity. Despite little interest from the pharmaceutical industry, 
Allison continued his intense efforts to develop the strategy 
into a therapy for humans. Promising results soon emerged 
from several groups, and in 2010 an important clinical study 
showed striking effects in patients with advanced melanoma. 
In several patients signs of remaining cancer disappeared. 
Such remarkable results had never been seen before in this 
patient group.
In 1992, a few years before Allison’s discovery, Tasuku 
Honjo discovered PD-1, another protein expressed on the sur-
face of T-cells. Determined to unravel its role, he meticulously 
explored its function in a series of elegant experiments per-
formed over many years in his laboratory at Kyoto University. 
The results showed that PD-1, similar to CTLA-4, functions 
as a T-cell brake, but operates by a different mechanism. In 
animal experiments, PD-1 blockade was also shown to be a 
promising strategy in the fight against cancer, as demonstrated 
by Honjo and other groups. This paved the way for utilizing 
PD-1 as a target in the treatment of patients. Results were 
dramatic, leading to long-term remission and possible cure 
in several patients with metastatic cancer.
After the initial studies showing the effects of CTLA-4 
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and PD-1 blockade, the clinical development has been dra-
matic. We now know that the immune checkpoint therapy 
has fundamentally changed the outcome for certain groups 
of patients with advanced cancer. Similar to other cancer 
therapies, adverse side effects are seen, which can be serious 
and even life threatening. They are caused by an overactive 
immune response leading to autoimmune reactions, but are 
usually manageable. Intense continuing research is focused on 
elucidating mechanisms of action, with the aim of improving 
therapies and reducing side effects.
Of the two treatment strategies, checkpoint therapy against 
PD-1 has proven more effective and positive results are being 
observed in several types of cancer, including lung cancer, 
renal cancer, lymphoma and melanoma. New clinical studies 
indicate that combination therapy, targeting both CTLA-4 and 
PD-1, can be even more effective, as demonstrated in patients 
with melanoma. A large number of checkpoint therapy trials 
are currently underway against most types of cancer, and new 
checkpoint proteins are being tested as targets.
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2) TAILORx: Phase III trial of chemoendocrine  
therapy versus endocrine therapy alone in hormone 
receptor-positive, HER2-negative, node-negative breast 
cancer and an intermediate prognosis  
21-gene recurrence score
In hormone receptor (HR)-positive, HER2-negative, axil-
lary node (AN)-negative breast cancer, the 21-gene expression 
assay (Oncotype DX Recurrence Score [RS]) is prognostic 
for distant recurrence, prognostic for low recurrence with 
endocrine therapy alone if low (0-10), and predictive of 
chemotherapy benefit if high (26 or higher).We performed a 
prospective, randomized trial of endocrine therapy (ET) versus 
chemoendocrine therapy (CET) in women with a mid-range 
RS of 11-25. Eligible patients (n=6711) were randomised 
to chemoendocrine therapy or endocrine therapy alone. The 
trial was designed to show the non-inferiority of endocrine 
therapy for the primary endpoint of 5-year invasive disease-
free survival (iDFS; freedom from invasive disease recurrence, 
second primary cancer, or death) with a non-inferiority mar-
gin of HR. Of the 10,253 eligible women enrolled between 
4/7/06-10/6/10, 6711 (65.5%) had a RS of 11-25 and adequate 
information. There were 836 iDFS events at final analysis 
with a median followup of 90 months. ET was non-inferior 
to CET for iDFS (HR 1.08, 95% confidence intervals [CI] 
0.94, 1.24, p=0.26) in the intention-to-treat (ITT) population. 
ET was also non-inferior for distant recurrence-free interval 
(DRFI; HR 1.03, p=0.80), recurrence-free interval (RFI; HR 
1.12, p=0.28), and overall survival (OS; HR 0.97, p=0.80). 
Nine year rates were similar for iDFS (83.3% vs. 84.3%), 
DRFI (94.5% vs. 95.0%), RFI (92.2% vs. 92.9%), and OS 
(93.9% vs. 93.8%). Recurrence accounted for 338 (41.6%) 
the first iDFS event, of which 199 (23.8%) were distant 
recurrences. Treatment interaction tests were significant for 
age (iDFS p=0.03; RFI p= 0.02), but not menopause, tumor 
size, grade, or RS (continuous or RS 11-15, 16-20, 21-25). 
In women with HR-positive, HER2-negative, AN-negative 
breast cancer and a RS of 11-25, adjuvant ET was not inferior 
to CET in the ITT analysis. The results of this trial mean that 
many women with early breast cancer do not need adjuvant 
chemotherapy, so avoiding the acute and chronic toxicities 
of the treatment.
The main barrier for the translation of the results to clinical 
practice in Australia is that Oncotype DX is not reimbursed 
and the private cost (~$4-5000) is prohibitive to most patients. 
This will hopefully change very soon.
3) CARMENA: Cytoreductive nephrectomy  
followed by sunitinib versus sunitinib alone  
in metastatic renal cell carcinoma—Results  
of a phase III noninferiority trial
Cytoreductive nephrectomy (CN) has been the standard of 
care in mRCC in the past twenty years, supported by random-
ized and large retrospective studies. However the efficacy of 
targeted therapies has challenged this standard. CARMENA 
was designed to answer the question of whether upfront CN 
should continue to be performed before sunitinib. CARMENA 
was a randomized phase III trial. Patients (pts) with synchro-
nous mRCC, amenable to CN, were enrolled after confirma-
tion of clear cell histology on biopsy if PS 0-1, absence of 
symptomatic brain metastasis, acceptable organ function and 
eligible for sunitinib therapy. Pts were randomized 1:1 to either 
CN followed by sunitinib (arm A) or sunitinib alone (arm B), 
and stratified by MSKCC risk groups. Sunitinib was given at 
50 mg/d, 4/6wk with dose adaptation to routine practice. In 
arm A, sunitinib had to start 4 to 6 wk after surgery. Primary 
endpoint was overall survival (OS). A total of 576 pts had to 
be enrolled to demonstrate non inferiority hypothesis Median 
age was 62, ECOG-PS was 0 in 56% and 1 in 44%. MSKCC 
risk groups were intermediate/poor in 55.6/44.4% (arm A) 
and in 58.5/41.5% (arm B). In arm A, 6.7% did not have CN 
and 22.5% never received sunitinib. In arm B, 4.9% never 
received sunitinib and 17% had secondary nephrectomy. 
At the time of the analysis, 326 deaths have been observed 
with a median follow-up of 50.9 mo. OS was not inferior in 
arm B, overall as well as by MSKCC risk groups (table). No 
difference in response rate and PFS was observed. Safety of 
sunitinib was as expected in both arms. Sunitinib alone is not 
inferior to CN followed by sunitinib in synchronous mRCC 
both in intermediate and poor MSKCC risk groups. CN should 
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not be anymore the standard of care when medical treatment 
is required. 
4) Unicancer GI PRODIGE 24/CCTG PA.6 trial:  
A multicenter international randomized  
phase III trial of adjuvant mFOLFIRINOX  
versus gemcitabine (gem) in patients with  
resected pancreatic ductal adenocarcinomas.
The Unicancer GI PRODIGE 24/CCTG PA.6 trial inves-
tigated the role of adjuvant modified FOLFIRINOX (mFOL-
FIRINOX) versus gemcitabine in resected pancreatic cancer. 
mFOLFIRINOX has no 5-FU bolus; during the trial the 
starting irinotecan dose was also reduced from 180mg/m2 
to 150mg/m2. The trial was designed to determine the supe-
riority of mFOLFIRINOX over gemcitabine with a primary 
endpoint of disease free survival (DFS). 493 patients were 
enrolled from 77 French and Canadian centres. Patients in 
the mFOLFIRINOX arm compared with the gemcitabine 
arm had higher use of G-CSF (59.9% v 3.7%, p<0.001) but 
similar rates of neutropenia and febrile neutropenia, overall 
more toxicity especially diarrhoea (eg gr ¾ 18.6% v 3.7%), 
and lower overall dose intensity (66.4% v 79.0%, p=0.002). 
mFOLFIRINOX improved DFS (median DFS 21.6 v 12.8 
months; HR 0.58; 95% CI 0.46-0.73, p<0.0001), OS (median 
OS 54.4 v 35 months; HR 0.64; 95% CI 0.48-0.86, p<0.003) 
and other secondary endpoints of metastasis free survival and 
specific survival. This trial was very well-received and was 
notable for the big improvements in survival with mFOL-
FIRINOX, the good performance of the control arm, and the 
benefits coming from good old chemotherapy. Despite the 
current standard of care being combination capecitabine and 
gemcitabine as per the ESPAC-4 trial, the results should have 
an immediate impact on clinical practice in Australia with 
mFOLFIRINOX the preferred adjuvant regimen for suitable 
patients. Conclusion: Adjuvant mFOLFIRINOX is safe and 
significantly improves DFS, MFS and OS compared to gem.
5) Dabrafenib and Trametinib Treatment in Patients 
With Locally Advanced or Metastatic BRAF V600-
Mutant Anaplastic Thyroid Cancer.
We report the efficacy and safety of dabrafenib (BRAF 
inhibitor) and trametinib (MEK inhibitor) combination therapy 
in BRAF V600E-mutated anaplastic thyroid cancer, a rare, 
aggressive, and highly lethal malignancy with poor patient 
outcomes and no systemic therapies with clinical benefit. In 
this phase II, open-label trial, patients with predefined BRAF 
V600E-mutated malignancies received dabrafenib 150 mg 
twice daily and trametinib 2 mg once daily until unacceptable 
toxicity, disease progression, or death. Sixteen patients with 
BRAF V600E-mutated anaplastic thyroid cancer were evalu-
able (median follow-up, 47 weeks; range, 4 to 120 weeks). All 
patients had received prior radiation treatment and/or surgery, 
and six had received prior systemic therapy. The confirmed 
overall response rate was 69% (11 of 16; 95% CI, 41% to 
89%), with seven ongoing responses. Median duration of 
response, progression-free survival, and overall survival were 
not reached as a result of a lack of events, with 12-month 
estimates of 90%, 79%, and 80%, respectively. The safety 
population was composed of 100 patients who were enrolled 
with seven rare tumor histologies. Common adverse events 
were fatigue (38%), pyrexia (37%), and nausea (35%). No 
new safety signals were detected.
These findings represent a meaningful therapeutic advance 
for this orphan disease. enrolling patients with rare cancers 
with the BRAF V600E mutation, including locally advanced, 
unresectable, or metastatic anaplastic thyroid cancer with no 
locoregional treatment options. The recommended doses for 
anaplastic thyroid cancer are 150 mg of dabrafenib orally twice 
daily and 2 mg of trametinib orally once daily. FDA granted on 
4 May 2018 this application priority review. FDA also granted 
breakthrough designation and orphan drug designation for the 
combination of dabrafenib and trametinib in the anaplastic 
thyroid cancer with BRAF V600 mutation indication. 
